SREBF2 and colorectal carcinoma: Similarly, in aggressive mesenchymal CRC, enhanced stabilization of SCAP and activation of SREBP2 also creates a cholesterol metabolic addiction and a therapeutic vulnerability (Muta et al., 2023).